ATOUT CAPITAL advised the shareholders of ABL DIAGNOSTICS in the context of an RTO (Reverse Take-Over) merger using the listed structure ABL DIAGNOSTICS, formerly known as ETABLISSEMENTS FAUVET-GIREL.
This merger of ABL FRANCE into ABL DIAGNOSTICS was approved by the AMF on July 12, 2022 and approved by the shareholders at the General Meeting held on August 3, 2022.
With a valuation of approximately €28 million retained for ABL FRANCE, this activity of development and marketing of diagnostic kits is now housed in the structure ABL DIAGNOSTICS whose shares are admitted to trading on compartment C of Euronext Paris (ISIN FR001400AHX6 – Mnémo ABLD) and could soon call on the market to finance the acceleration of its development.
